Cui G F, He B X, Wu F E
Affiliated Hospital, Xingjiang Medical College, Urumqi.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993 May;13(5):281-3, 261.
92 cases with complete clinical data among 125 hyperlipemia patients were randomly divided into two groups: 51 cases in the Xue Zhi Ling treatment group and 41 cases in the control group with medication of panagin. The drugs were administered to all patients for 12 weeks and the blood lipid was then examined at the 4th, 8th, 12th week after medication respectively. In treatment group, there was the effect of lowering TC, TC-HDL/HDL and raising HDL at the 4th week (P < 0.05). However, there were no significant difference in above-mentioned parameters at the 4th, 8th and 12th week respectively. The experiment also showed that Xue Zhi Ling could reduce TG at the 8th and 12th week (P < 0.05). While there was no significant difference between that of the 8th and 12th weeks. The mean reduction of TC, TG and TC-HLD/HDL were 18.7%, 19.5% and 27.6% respectively, while the elevation of HDL in average was 17.4%. All of the lipid indexes in control group had no significant changes at any stage. In addition, it was shown that Xue Zhi Ling could decrease serum LPO at 12th week (P < 0.05). The results indicated that the Xue Zhi Ling has the effect of regulating the hyperlipemia and anti-oxidation.
125例高脂血症患者中,92例具有完整临床资料者被随机分为两组:血脂灵治疗组51例,对照组41例,给予泛癸利酮治疗。所有患者均用药12周,分别于用药后第4、8、12周检测血脂。治疗组在第4周时具有降低总胆固醇(TC)、TC-高密度脂蛋白胆固醇(HDL)/HDL及升高HDL的作用(P<0.05)。然而,在第4、8、12周时上述指标分别无显著差异。实验还显示,血脂灵在第8周和第12周时可降低甘油三酯(TG)(P<0.05)。而第8周和第12周时TG降低情况无显著差异。TC、TG及TC-HLD/HDL的平均降低率分别为18.7%、19.5%和27.6%,而HDL的平均升高率为17.4%。对照组在任何阶段所有血脂指标均无显著变化。此外,结果显示血脂灵在第12周时可降低血清脂质过氧化物(LPO)(P<0.05)。结果表明,血脂灵具有调节高脂血症及抗氧化作用。